Citalopram versus other anti-depressive agents for depression

Abstract

Background Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode. Systematic reviews have already highlighted some differences in efficacy between second-generation antidepressants. Citalopram, one of the first selective serotonin reuptake inhibitors (SSRI) introduced in the market, is one of these antidepressant drugs that clinicians use for routine depression care. Objectives To assess the evidence for the efficacy, acceptability and tolerability of citalopram in comparison with tricyclics, heterocyclics, other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression. Search methods We searched The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register and the Cochrane Central Register of Controlled Trials up to February 2012. No language restriction was applied. We contacted pharmaceutical companies and experts in this field for supplemental data. Selection criteria Randomised controlled trials allocating patients with major depression to citalopram versus any other antidepressants. Data collection and analysis Two reviewers independently extracted data. Information extracted included study characteristics, participant characteristics, intervention details and outcome measures in terms of efficacy (the number of patients who responded or remitted), patient acceptability (the number of patients who failed to complete the study) and tolerability (side-effects). Main results Thirty-seven trials compared citalopram with other antidepressants (such as tricyclics, heterocyclics, SSRIs and other antidepressants, either conventional ones, such as mirtazapine, venlafaxine and reboxetine, or non-conventional, like hypericum). Citalopram was shown to be significantly less effective than escitalopram in achieving acute response (odds ratio (OR) 1.47, 95% confidence interval (CI) 1.08 to 2.02), but more effective than paroxetine (OR 0.65, 95% CI 0.44 to 0.96) and reboxetine (OR 0.63, 95% CI 0.43 to 0.91). Significantly fewer patients allocated to citalopram withdrew from trials due to adverse events compared with patients allocated to tricyclics (OR 0.54, 95% CI 0.38 to 0.78) and fewer patients allocated to citalopram reported at least one side effect than reboxetine or venlafaxine (OR 0.64, 95% CI 0.42 to 0.97 and OR 0.46, 95% CI 0.24 to 0.88, respectively). Authors’ conclusions Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy, tolerability and acceptability. Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics, reboxetine and venlafaxine, however, it seemed to be less efficacious than escitalopram. As with most systematic reviews in psychopharmacology, the potential for overestimation of treatment effect due ...

Selective Serotonin Reuptake Inhibitors, are They All Equal? A Pharmacoepidemiological Study

“…The superiority of escitalopram over other SSRIs has been demonstrated in head to head efficacy trials and meta-analyses [18][19][20]22,23,[32][33][34]. Escitalopram is the most specific SSRI, because of its unique pharmacological property: selected serotonin reuptake inhibition [11].…”

“…All other RCTs found no significant differences in safety or efficacy between SSRIs: escitalopram and fluoxetine [25,26]; citalopram and sertraline [27]; fluoxetine and sertraline [28]; fluoxetine, sertraline and paroxetine [29] and fluvoxamine, sertraline and paroxetine [30]. Metaanalyses [31,[32][33][34][35][36] have also been published, two of them did not find any differences between SSRIs, while the others concluded with the superiority of escitalopram.…”

Exploring Standardized Zembrin® Extracts from the South African plant Sceletium tortuosum in Dual Targeting Phosphodiesterase-4 (PDE-4) and Serotonin Reuptake Inhibition as potential treatment in Schizophrenia

“…Mesembrenone and mesembranol were found to be much weaker in the 5-HT transport site in vitro [44]. The efficacy of Selective Serotonin Reuptake Inhibitors (SSRI) in the treatment of anxiety and depressive disorders is well documented [45]. More recently escitalopram, the putative SSRI, has been shown to improve cognition and facilitate post-stroke recovery [46].…”

Mindfulness-Based Cognitive Therapy in Major depressive disorder - systematic review and metanalysis

“…Although psychological interventions are effective in the treatment of MDD, the prescription of antidepressant drugs is the mainstay of treatment to prevent relapse and recurrence (12), however, this may present some limitations, such as poor adherence and side effects (13).…”